2023-05-15 08:58:54 ET
- Thorne HealthTech ( NASDAQ: THRN ) is experiencing a 5.2% increase in premarket trading following its recent collaboration announcement.
- The company entered into a research and development partnership agreement with Arome Science, a metabolomics data acquisition firm. Together, they aim to develop an advanced metabolomics test.
- Thorne HealthTech ( THRN ) and Arome Science have joined forces in a groundbreaking collaboration aimed at revolutionizing metabolomics analysis. Their upcoming test will have a pivotal role in supporting research studies that employ Thorne's innovative OneDraw medical device for at-home blood collection.
- The partnership's primary objective is to advance and validate the metabolomics test, with the ultimate vision of making it accessible to consumers in the near future. This significant development represents a major stride forward in delivering comprehensive and easily accessible metabolomics analysis for individuals .
For further details see:
Thorne HealthTech surges 5.2% as it partners with Arome Science to advance metabolomics testing